Paper41007647
Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions.
Alsadder L and 1 other. Biomedicines, 2025. Cited by 22 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions. Papers, record 41007647. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007647
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07898709 | Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI | Background |
Source ClinicalTrials.gov
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,344,955 | Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities. | World J Cardiol | 2018 | https://conductscience.org/library/papers/30344955 | PubMed |
| 2 | 2,939,955 | Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischaemia. | Cardiovasc Res | 1986 | https://conductscience.org/library/papers/2939955 | PubMed |
| 3 | 33,309,175 | Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. | J Am Coll Cardiol | 2020 | https://conductscience.org/library/papers/33309175 | PubMed |
| 4 | 36,835,150 | Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36835150 | PubMed |
| 5 | 32,892,450 | A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment. | Cell Biochem Funct | 2021 | https://conductscience.org/library/papers/32892450 | PubMed |
| 6 | 24,140,081 | Small and large animal models in cardiac contraction research: advantages and disadvantages. | Pharmacol Ther | 2014 | https://conductscience.org/library/papers/24140081 | PubMed |
| 7 | 25,446,182 | The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. | J Mol Cell Cardiol | 2015 | https://conductscience.org/library/papers/25446182 | PubMed |
| 8 | 31,948,043 | Pathological Roles of Mitochondrial Oxidative Stress and Mitochondrial Dynamics in Cardiac Microvascular Ischemia/Reperfusion Injury. | Biomolecules | 2020 | https://conductscience.org/library/papers/31948043 | PubMed |
| 9 | 37,163,250 | CRISPR Editing Takes Aim at Ischemia/Reperfusion Injury. | JAMA Cardiol | 2023 | https://conductscience.org/library/papers/37163250 | PubMed |
| 10 | 26,674,987 | Reducing myocardial infarct size: challenges and future opportunities. | Heart | 2016 | https://conductscience.org/library/papers/26674987 | PubMed |
| 11 | 38,424,184 | Advances in AI and machine learning for predictive medicine. | J Hum Genet | 2024 | https://conductscience.org/library/papers/38424184 | PubMed |
| 12 | 25,236,884 | Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. | Circ Heart Fail | 2014 | https://conductscience.org/library/papers/25236884 | PubMed |
| 13 | 28,639,948 | Protective effects of IL28RA siRNA on cardiomyocytes in hypoxia/reoxygenation injury. | Anatol J Cardiol | 2017 | https://conductscience.org/library/papers/28639948 | PubMed |
| 14 | 38,153,307 | Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. | Physiol Rev | 2024 | https://conductscience.org/library/papers/38153307 | PubMed |
| 15 | 30,683,110 | Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. | J Nanobiotechnology | 2019 | https://conductscience.org/library/papers/30683110 | PubMed |
| 16 | 38,372,344 | Myocardial Ischemia/Reperfusion Injury: Mechanism and Targeted Treatment for Ferroptosis. | Anatol J Cardiol | 2024 | https://conductscience.org/library/papers/38372344 | PubMed |
| 17 | 33,354,280 | Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment. | Oxid Med Cell Longev | 2020 | https://conductscience.org/library/papers/33354280 | PubMed |
| 18 | 33,365,329 | Experimental Rodent Models of Cardiovascular Diseases. | Front Cardiovasc Med | 2020 | https://conductscience.org/library/papers/33365329 | PubMed |
| 19 | 34,623,181 | Guidelines for in vivo mouse models of myocardial infarction. | Am J Physiol Heart Circ Physiol | 2021 | https://conductscience.org/library/papers/34623181 | PubMed |
| 20 | 34,019,794 | Cardioids reveal self-organizing principles of human cardiogenesis. | Cell | 2021 | https://conductscience.org/library/papers/34019794 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,891,471 | Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials. | Cureus | 2026 | https://conductscience.org/library/papers/42891471 | PubMed |
| 42,807,805 | RAGE signaling in acute myocardial infarction: sRAGE as a dynamic biomarker and emerging therapeutic target. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42807805 | PubMed |
| 42,791,187 | Single-Cell and Bulk RNA-Seq Profiling Identifies Cell Adhesion-Related Gene Signatures in Cerebral Ischemia-Reperfusion Injury. | eNeuro | 2026 | https://conductscience.org/library/papers/42791187 | PubMed |
| 42,707,998 | Clinically recommended strategies for nutritional metabolic intervention in cardiac surgery: a narrative review of oral support agents and modulators on postoperative outcomes and mechanisms. | Front Nutr | 2026 | https://conductscience.org/library/papers/42707998 | PubMed |
| 42,694,485 | Dynamic trajectories of inflammatory biomarkers and post-stroke cognitive impairment: a comprehensive review of neuroimmune mechanisms, longitudinal modeling, and clinical translation. | Front Neurol | 2026 | https://conductscience.org/library/papers/42694485 | PubMed |
| 42,652,143 | Evaluation of Early and Delayed Meloxicam Treatment Against Regulated Cell Death Pathways and ERK1/2 Phosphorylation in a Rat Model of Renal Ischemia-Reperfusion Injury. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652143 | PubMed |
| 42,650,193 | From Exposure to Outcome: Air Pollution-Induced Oxidative Stress as a Determinant of Early and Late Outcomes After Coronary Artery Bypass Grafting. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42650193 | PubMed |
| 42,589,368 | SEM1 Downregulates HSPA8 to Suppress TLR4/MyD88/NF-κB Signaling and Alleviate Myocardial I/R Injury. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589368 | PubMed |
| 42,584,557 | Protective mechanisms of Sirtuin Family in myocardial ischemia-reperfusion injury and translational therapeutic perspectives. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42584557 | PubMed |
| 42,439,682 | Effects of Prolonged Normobaric Hypoxia and Norepinephrine on the Rat Heart-Can They Be Reversed by Normoxic Recovery? | Cells | 2026 | https://conductscience.org/library/papers/42439682 | PubMed |
| 42,351,811 | Inflammation-Based C-Reactive Protein-to-Albumin Ratio for No-Reflow Prediction in STEMI. | Biomedicines | 2026 | https://conductscience.org/library/papers/42351811 | PubMed |
| 42,321,347 | Biomimetic macrophage membrane-coated nanoparticles for targeted cardioprotection against myocardial ischaemia-reperfusion injury. | Sci Rep | 2026 | https://conductscience.org/library/papers/42321347 | PubMed |
| 42,278,197 | O-GlcNAcylation as a Metabolic Integrator in Cardiovascular Physiology and Disease. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278197 | PubMed |
| 42,193,950 | PPARα: Linking Cardiac Metabolism to Therapeutic Opportunities in Cardiovascular Diseases. | Cells | 2026 | https://conductscience.org/library/papers/42193950 | PubMed |
| 42,175,629 | Kaempferol Attenuates Myocardial Ischemia-Reperfusion Injury by Suppressing Ferroptosis via the KEAP1-Nrf2-GPX4 Axis. | Kaohsiung J Med Sci | 2026 | https://conductscience.org/library/papers/42175629 | PubMed |
| 42,136,714 | A cost-effective proof-of-concept ex vivo perfusion model for myocardial ischemia-reperfusion injury in wistar rats: enhancing accessibility in resource-constrained settings. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42136714 | PubMed |
| 41,906,488 | The Protective Effect of Carvacrol Against Isoproterenol-Induced Cardiotoxicity in Rats. | Medeni Med J | 2026 | https://conductscience.org/library/papers/41906488 | PubMed |
| 41,898,150 | Cardiovascular Diseases: From Pathophysiology to Novel Therapeutic Approaches. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898150 | PubMed |
| 41,694,766 | Oxycodone: A Pain-Relieving Agent With Cardioprotective Properties Against Myocardial Ischemia-Reperfusion Injury. | Cardiovasc Ther | 2026 | https://conductscience.org/library/papers/41694766 | PubMed |
| 41,655,822 | Pathophysiological significance of the TRPM2 ion channel as a potential target in cancer, neurological disorders, and ischemia/reperfusion injury. | Pharmacol Res | 2026 | https://conductscience.org/library/papers/41655822 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007647
GET https://conductscience.org/api/papers/v1/41007647/references?page=2